Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation

Seok Beom Yong, Hyung Jin Kim, Jang Kyoung Kim, Jee Young Chung, Yong Hee Kim*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


A subset of phagocytes including inflammatory monocytes in blood migrate and give rise to macrophages in inflammatory tissues which generated the idea that blood monocytes are the therapeutic targets for drug delivery. Fc gamma receptor I (CD64) is a membrane receptor for the Fc region of immunoglobulin G, primarily expressed on monocyte-lineage, and H22 a monoclonal antibody for human CD64 had shown rapid blood monocyte binding and occupation in clinical studies. Small interfering RNA-mediated gene silencing as a therapeutic has been proposed and is a promising strategy in terms of its "knock-down" ability on the target gene prior to translation. However, its instability and off-targeting effect must be overcome for success in clinical studies. In this study, we developed a non-viral delivery system composed of oligo-nona-arginine (9R) and anti-human CD64 single chain antibodies (H22) for human monocyte-specific siRNA delivery. A targeted and efficient siRNA delivery mediated by anti-CD64 scFv-9R was observed in CD64 positive human leukemia cells, THP-1. With primary human blood cells, anti-CD64 scFv-9R mediated gene silencing was quantitatively confirmed representing blood monocyte selective gene delivery. These results demonstrate the potential of anti-CD64 scFv-9R mediated siRNA delivery for the treatment of human inflammatory diseases via blood monocytes gene delivery.

Original languageEnglish
Article number42171
JournalScientific Reports
StatePublished - 7 Feb 2017
Externally publishedYes


Dive into the research topics of 'Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation'. Together they form a unique fingerprint.

Cite this